GKT771 is a potent and highly selective inhibitor of NOX1 which has recently been selected as a preclinical development candidate.This adds another drug candidate to our NOX pipeline enabling us to address a range of diseases driven by NOX1-dependent angiogenic and inflammatory processes. Genkyotex intends to submit a clinical trial application in 2018.